Rakuten Medical: Cancer Treatment Collaboration with Taiwan Firm
- Rakuten Medical is collaborating with Orient Europharma (OEP), a Taiwanese drugmaker, to broaden the availability of its cancer immunotherapy treatment across Asia.
- The agreement allows OEP to develop and sell Rakuten Medical's drugs and devices in Singapore, Malaysia, the Philippines, and Taiwan.
- The collaboration between rakuten Medical and Orient Europharma is expected to accelerate the growth and commercialization of new cancer treatments in the specified Asian countries.
Rakuten Medical teams up with Taiwanese firm Orient Europharma to dramatically expand access to its cancer immunotherapy across Asia, a deal finalized this Wednesday. This crucial partnership will see Rakuten Medical’s drugs and devices available in Singapore, Malaysia, the Philippines, and Taiwan, targeting improved cancer care through innovative methods. This move signals a meaningful stride in making advanced cancer treatments more accessible in key Asian markets. News Directory 3 is following this groundbreaking collaboration closely. The partnership aims to accelerate growth and commercialization, offering hope to patients in these regions. What medical breakthroughs will emerge from this collaboration? Discover what’s next for cancer treatment in Asia.
Rakuten Medical Expands Immunotherapy Reach in Asia
Updated June 25, 2025
Rakuten Medical is collaborating with Orient Europharma (OEP), a Taiwanese drugmaker, to broaden the availability of its cancer immunotherapy treatment across Asia. The companies finalized an exclusive licensing agreement Wednesday.
The agreement allows OEP to develop and sell Rakuten Medical’s drugs and devices in Singapore, Malaysia, the Philippines, and Taiwan. this partnership aims to improve access to advanced cancer care in these key Asian markets, focusing on innovative immunotherapy methods.
What’s next
The collaboration between rakuten Medical and Orient Europharma is expected to accelerate the growth and commercialization of new cancer treatments in the specified Asian countries. Patients in these regions may soon have access to more advanced immunotherapy options.